Clinical Trial Update: Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating a single daily dose of rifaximin for travelers' diarrhea has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Travelers Diarrhea

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Travelers' Diarrhea | Phase 4 | Status: WITHDRAWN